Scientific Director GSK, Pennsylvania, United States
Disclosure(s):
Vivaswath S. Ayyar, PhD: No relevant disclosure to display
QSP has firmly established its value in oncology, contributing to drug development, mechanistic understanding, and regulatory decisions. Yet, many complex disease areas outside oncology - such as immunology, infectious diseases, neurodegeneration, and cardiometabolic-renal conditions - pose equally urgent challenges in clinical pharmacology. These include predicting efficacy in heterogeneous patient populations, optimizing combination strategies, addressing comorbidities, and benchmarking therapies in competitive landscapes. This opening talk will set the stage for the session by exploring how QSP is uniquely positioned to address these needs and drive model-informed drug development in non-oncology areas. Framed around four key pillars - mechanistic insight, data-driven qualification, credibility, and drug development impact, this talk will prepare the foundation for the disease-focused talks to follow.
